CD44 and neoplasm: These obtained results strongly recommended that an enhancement in the efficacy TeHA-SLNs/DTX against tumor cells was strongly reliant on the specific interactions between TeHA ligands and CD44/αvβ3 receptors, both ligands did not inhibit the interactions with their particular target but exhibited a synergistic dual active targeting effect (Shi et al., 2016).